TrialNature communications2024

A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.

Lavinia Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.